S. Cannistra

发表

Advances in the management of epithelial ovarian cancer.

A. Berkenblit, S. Cannistra, 2005, The Journal of reproductive medicine.

Gene-expression profiling in epithelial ovarian cancer

S. Cannistra, P. Konstantinopoulos, D. Spentzos, 2008, Nature Clinical Practice Oncology.

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

B. Karlan, D. Levine, S. Cannistra, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRCA1 mutations and survival in women with ovarian cancer.

S. Cannistra, 1997, The New England journal of medicine.

Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer

John Quackenbush, Lin Zhang, G. Coukos, 2011, PloS one.

Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

Marie Joseph, Douglas A Levine, Dimitrios Spentzos, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Douglas A Levine, Dimitrios Spentzos, H. Otu, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins.

S. Cannistra, B. Druker, J. Griffin, 1990, Blood.

Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

S. Cannistra, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells.

S. Cannistra, J. Griffin, M. Koenigsmann, 1990, The Journal of biological chemistry.

Chronic myelogenous leukemia as a model for the genetic basis of cancer.

S. Cannistra, 1990, Hematology/oncology clinics of North America.

Medical progress : cancer of the ovary

S. Cannistra, 1993 .

Enrichment for DNA mismatch repair‐deficient cells during treatment with cisplatin

S. Cannistra, S. Wilczynski, M. Haas, 1998, International journal of cancer.

Challenges and pitfalls of combining targeted agents in phase I studies.

S. Cannistra, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN

M. Socinski, S. Cannistra, A. Elias, 1988, The Lancet.

The biology of GM-CSF: regulation of production and interaction with its receptor.

G. Demetri, S. Cannistra, J. Griffin, 1990, International journal of cell cloning.

Characterization of adhesion molecules on human myeloma cell lines.

K. Anderson, S. Cannistra, D. Chauhan, 1992, Blood.

Characterization of adhesion molecules on human myeloma cell lines.

K. Anderson, S. Cannistra, D. Chauhan, 1992 .

Reply to C.M. Booth et al.

S. Cannistra, E. Small, K. Ballman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer of the uterine cervix.

J. Niloff, S. Cannistra, 1996, The New England journal of medicine.

Gynecologic malignancies

S. Cannistra, M. Shea, S. Bouberhan, 2022, Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease.

Bevacizumab rechallenge after first line maintenance bevacizumab.

S. Cannistra, U. Matulonis, P. Konstantinopoulos, 2012, Gynecologic oncology.

Gynecologic oncology or medical oncology: what's in a name?

S. Cannistra, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.

S. Cannistra, D. Kufe, Y. Tai, 1999, Cancer research.

BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death.

S. Cannistra, S. Kraeft, L. B. Chen, 1998, Cancer research.

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

S. Cannistra, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional heterogeneity of CD44 molecules in ovarian cancer cell lines.

J. Niloff, S. Cannistra, B. DeFranzo, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Progress in the Management of Gynecologic Cancer

S. Cannistra, W. Mcguire, 2007 .

Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.

J. Niloff, A. Berkenblit, S. Cannistra, 2003, Gynecologic oncology.

Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.

J. Niloff, R. Berkowitz, S. Cannistra, 2000, Gynecologic oncology.

Back to the future: multiagent chemotherapy in ovarian cancer revisited.

S. Cannistra, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

J. Niloff, K. Anderson, G. Demetri, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

dependent mechanism stimulate monocyte cytotoxicity through a tumor necrosis factor- Human granulocyte-monocyte colony-stimulating factor and interleukin 3

E. Vellenga, S. Cannistra, J. Griffin, 2011 .

Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism.

E. Vellenga, S. Cannistra, J. Griffin, 1988, Blood.

Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line.

S. Cannistra, B. Druker, J. Griffin, 1991, The Journal of biological chemistry.

Performance of biopsies in clinical research.

S. Cannistra, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

leukemia: direct analysis using partially purified colony- forming cells Expression of Ia antigens on myeloid progenitor cells in chronic myeloid

S. Cannistra, J. Griffin, J. Daley, 2011 .

Differential expression of HLA-DR antigens in subsets of human CFU-GM.

S. Cannistra, F. Herrmann, J. Griffin, 1985, Blood.

Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony- forming cells

S. Cannistra, J. Griffin, J. Daley, 1985 .

Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells.

S. Cannistra, J. Griffin, J. Daley, 1985, Blood.

Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.

S. Cannistra, J. Griffin, P. Groshek, 1989, Leukemia.

Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors.

E. Vellenga, S. Cannistra, J. Griffin, 1987, Blood.

The ethics of early stopping rules: who is protecting whom?

S. Cannistra, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vascular cell adhesion molecule-1 expressed by peritoneal mesothelium partly mediates the binding of activated human T lymphocytes.

S. Cannistra, C. Ottensmeier, J. Tidy, 1994, Experimental hematology.

Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes.

S. Cannistra, F. Herrmann, J. Griffin, 1987, The Journal of clinical investigation.

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.

Cesar M. Castro, S. Cannistra, U. Matulonis, 2019, JAMA oncology.

Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells

S. Cannistra, F. Herrmann, J. Griffin, 1985, The Journal of experimental medicine.

Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.

S. Cannistra, P. Konstantinopoulos, M. Hacker, 2011, Journal of minimally invasive gynecology.

Intraperitoneal chemotherapy comes of age.

S. Cannistra, 2006, The New England journal of medicine.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Howard Mackey, R. Burger, R. Wenham, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.

S. Cannistra, Joyce F. Liu, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab in patients with advanced platinum-resistant ovarian cancer.

R. Burger, R. Wenham, S. Cannistra, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A feasibility study of low‐dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum‐based chemotherapy

S. Cannistra, A. Comander, 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.

S. Cannistra, E. Pujade-Lauraine, S. Bouberhan, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges Faced by Medical Journals During the COVID-19 Pandemic.

S. Cannistra, K. Ballman, B. Haffty, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulosa C ell T umor o f t he O vary

S. Cannistra, S. Schumer, 2003 .

Estrogen receptor expression is a common feature of ovarian borderline tumors.

J. Niloff, S. Cannistra, G. Abu-Jawdeh, 1996, Gynecologic oncology.

Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistance in chronic myeloid leukemia.

S. Cannistra, F. Herrmann, J. Griffin, 1986, The Journal of clinical investigation.

Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 receptors.

S. Cannistra, F. Herrmann, M. Brach, 1989, Haematology and blood transfusion.

Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.

S. Cannistra, J. Griffin, R. Mayer, 1991, Leukemia.

T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro.

S. Cannistra, F. Herrmann, J. Griffin, 1986, Journal of immunology.

Absence of constitutive EGF receptor activation in ovarian cancer cell lines.

J. Niloff, S. Cannistra, B. Druker, 1996, British Journal of Cancer.

Regulation of the production and function of granulocytes and monocytes.

S. Cannistra, J. Griffin, James D. Griffin, 1988, Seminars in hematology.

Interferon‐γ induces expression of the interleukin 2 receptor gene in human monocytes

S. Cannistra, F. Herrmann, J. Griffin, 1987 .

Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells.

S. Cannistra, J. Griffin, J. Miller, 1990, Proceedings of the National Academy of Sciences of the United States of America.

In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells.

G. Demetri, S. Cannistra, J. Griffin, 1988, Experimental hematology.

Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2.

S. Cannistra, F. Herrmann, J. Griffin, 1989, Journal of immunology.

Hematologic remission and cytogenetic improvement after treatment of stable‐phase chronic myelogenous leukemia with continuous infusion of low‐dose cytarabine

S. Cannistra, J. Griffin, M. Robertson, 1993, American journal of hematology.

BRCA-1 in Sporadic Epithelial Ovarian Cancer: Lessons Learned from the Genetics of Hereditary Disease

S. Cannistra, 2007, Clinical Cancer Research.

Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors.

S. Cannistra, U. Matulonis, N. Horowitz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progress in the management of gynecologic cancer: consensus summary statement.

R. Bast, S. Skates, J. Garber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulosa cell tumor of the ovary.

S. Cannistra, Stephen A Cannistra, Susan Tinsley Schumer, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.

S. Korsmeyer, S. Cannistra, S. Korsmeyer, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.

M. Socinski, S. Cannistra, J. Griffin, 1988, The New England journal of medicine.

Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor.

S. Cannistra, J. Griffin, P. Groshek, 1988, Experimental hematology.

Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.

J. Niloff, S. Cannistra, C. Ottensmeier, 1993, Cancer research.

Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro.

S. Cannistra, T. Strobel, 1999, Gynecologic oncology.

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer

T. Libermann, S. Cannistra, L. Zerbini, 2008, BMC Medical Genomics.

Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases

S. Cannistra, C. Eng, T. Prior, 2001, Human Genetics.

Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.

S. Cannistra, C. Eng, E. Maher, 2001, The American journal of pathology.

Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo.

M. Socinski, S. Cannistra, J. Griffin, 1988, Blood.

Location of BRCA1 in Human Breast and Ovarian Cancer Cells

C. Osborne, S. Schnitt, D. Livingston, 1996, Science.

Expression and Function of 1 and av3 Integrins in Ovarian Cancer

J. Niloff, S. Cannistra, C. Ottensmeier, 1995 .

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.

S. Cannistra, N. Lindeman, U. Matulonis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.

S. Cannistra, P. Konstantinopoulos, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.

Percy Ivy, A. Berkenblit, S. Cannistra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.

C. Mantzoros, T. Libermann, D. Levine, 2007, Endocrine-related cancer.

BAX protein expression and clinical outcome in epithelial ovarian cancer.

S. Cannistra, Y. Tai, T. Strobel, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

When is a "prognostic factor" really prognostic?

S. Cannistra, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer of the ovary.

S. Cannistra, 1993, The New England journal of medicine.

Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.

S. Cannistra, J. Hecht, P. Konstantinopoulos, 2011, Cancer research.

A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer.

S. Cannistra, N. Horowitz, P. Konstantinopoulos, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

A. Berkenblit, S. Cannistra, U. Matulonis, 2004, Gynecologic oncology.

Phase II trials in journal of clinical oncology.

S. Cannistra, Stephen A Cannistra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?

S. Cannistra, N. Tung, K. DeLeonardis, 2019, Journal of oncology practice.

CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors.

J. Niloff, S. Cannistra, G. Abu-Jawdeh, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model.

J. Ritz, S. Cannistra, D. Roy, 1990, Leukemia research.

Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I.

S. Cannistra, J. Griffin, M. Koenigsmann, 1992, Blood.

Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?

S. Cannistra, M. Shea, S. Bouberhan, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel in ovarian cancer: how can we make it better?

S. Cannistra, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAD partly reverses paclitaxel resistance in human ovarian cancer cells

S. Korsmeyer, S. Cannistra, Y. Tai, 1998, Oncogene.

Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells

S. Korsmeyer, S. Cannistra, T. Strobel, 1997, Oncogene.

"Cancer defeated": not if, but when--introducing the Biology of Neoplasia series.

S. Cannistra, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progress and Promise in Treating Gynecologic Cancers.

S. Cannistra, E. Pujade-Lauraine, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.

S. Cannistra, U. Matulonis, N. Horowitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity1

S. Cannistra, D. Kufe, Dongshu Chen, 2000, The Journal of Immunology.

Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes.

S. Cannistra, F. Herrmann, J. Griffin, 1987, European journal of immunology.

Identification of functionally distinct domains of human granulocyte- macrophage colony-stimulating factor using monoclonal antibodies

S. Cannistra, J. Griffin, K. Kaushansky, 1991 .

Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies.

S. Cannistra, J. Griffin, K. Kaushansky, 1991, Blood.

Association between clonogenic cell growth and clinical risk group in B-cell chronic lymphocytic leukemia.

S. Cannistra, A. Freedman, L. Nadler, 1990, Blood.

Studies Keap 1 Mutations and Nrf 2 Pathway Activation in Epithelial Ovarian Cancer

S. Cannistra, J. Hecht, P. Konstantinopoulos, 2011 .

Clinical Studies Keap 1 Mutations and Nrf 2 Pathway Activation in Epithelial Ovarian Cancer

S. Cannistra, J. Hecht, P. Konstantinopoulos, 2011 .

Why should the clonogenic cell assay be prognostically important in ovarian cancer?

S. Cannistra, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer.

J. Niloff, S. Cannistra, C. Ottensmeier, 1995, Gynecologic oncology.

In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.

S. Cannistra, T. Strobel, L. Swanson, 1997, Cancer research.

LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer

Cesar M. Castro, S. Cannistra, U. Matulonis, 2020 .

Growth regulation of malignant clonogenic cells in acute myeloid leukemia

S. Cannistra, 1991, Current opinion in oncology.

Cancer of the ovary.

S. Cannistra, S A Cannistra, Stephen A. Cannistra, 1993, The New England journal of medicine.

Maintenance PARP inhibitor therapy: is maintaining quality of life enough?

S. Cannistra, M. Shea, S. Bouberhan, 2018, The Lancet. Oncology.

Phase I studies of drug combinations.

J. Verweij, S. Cannistra, M. Disis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAX enhances paclitaxel-induced apoptosis through a p 53-independent pathway ( drug resistance y chemotherapy y ovarian y cancer )

S. Korsmeyer, S. Cannistra, T. Strobel, 1996 .

Evaluation of treatment benefit in Journal of Clinical Oncology.

S. Cannistra, E. Small, K. Ballman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers

S. Cannistra, U. Matulonis, N. Horowitz, 2007 .

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer

T. Libermann, S. Cannistra, L. Zerbini, 2008 .

Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer

M. Birrer, S. Cannistra, William H. Barry, 2018, Gynecologic Oncology.

Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

S. Cannistra, P. Konstantinopoulos, 2021, Journal of Clinical Oncology.

Advances in Brief In Vivo Inhibition of CD 44 Limits Intra-Abdominal Spread of a Human Ovarian Cancer Xenograft in Nude Mice : A Novel Role for CD 44 in the Process of Peritoneal Implantation 1

S. Cannistra, T. Strobel, L. Swanson, 2006 .

New initiatives at Journal of Clinical Oncology.

S. Cannistra, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.

S. Cannistra, U. Matulonis, N. Horowitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.

S. Cannistra, J. Hecht, P. Konstantinopoulos, 2011, Cancer research.